Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Protein kinases play vital roles in cellular signaling, with dysregulation implicated in cancer.
• Microtubule-affinity regulating kinase 4 (MARK4) is a Ser/Thr kinase involved in key signaling pathways (NF-κB, mTOR, Hippo).
• Aberrant MARK4 expression is linked to cancer, Alzheimer's disease, and obesity.

Purpose of the Study:

• To review the structural aspects and signaling roles of MARK4 in cancer.
• To highlight MARK4-targeted drug discovery and development in oncology.
• To summarize MARK4's role in cancer, diabetes, and neurodegenerative diseases for future therapeutic strategies.

Main Methods:

• Literature review of structural biology, signaling pathways, and therapeutic interventions related to MARK4.
• Analysis of MARK4's involvement in microtubule dynamics and cell division.
• Exploration of kinase-targeted drug discovery for MARK4 inhibition.

Main Results:

• MARK4 regulates microtubule dynamics and cell division, contributing to various cancer types.
• MARK4's aberrant expression is associated with multiple pathologies, including cancer and neurodegenerative diseases.
• Development of small-molecule inhibitors targeting MARK4 demonstrates therapeutic promise.

Conclusions:

• MARK4 is a significant therapeutic target for oncology and other diseases.
• Targeted inhibition of MARK4 offers a promising strategy for drug discovery.
• Further research into MARK4's role in cancer, diabetes, and neurodegeneration is warranted for therapeutic intervention.